Page 11234..1020..»

Category Archives: Psoriasis

‘Scandal’ actress Katie Lowes opens up about psoriasis – WATE 6 On Your Side

Posted: June 24, 2017 at 1:49 pm

KNOXVILLE (WATE) Quinn Perkins, played by Actress Katie Lowes is one tough cookie on the show Scandal, but she is also tough in real life.

Lowes has lived with a chronic autoimmune disease known as psoriasis for the past eight years. She says she was diagnosed with psoriasis eight years ago but finally decided to go public with her experiences in the hopes of helping others.

When I was first diagnosed I was so embarrassed and ashamed. You know, being an actress in Hollywood, there is such a pressure to look a certain way and after living with it for eight years, says Lowes, Im really living my best life and I thought there are 7.5 million other Americans living with this disease and if I can help even one of them feel inspired to be there own best advocate to get to a place where they are living their fullest life and theyre not limiting themselves because of psoriasis, then that would just be a huge win.

The actress is partnering with Jansen and the National Psoriasis Foundation on a campaign called Inside Story. She shares her story about living with psoriasis and encourages others to do the same.

While on the set of Scandal, Lowes said there were times when she had flare-ups. She said there were times when she couldnt wear a certain red carpet look or wear a bathing suit on vacation.

There are all these limitations placed on your life and I know from personal experience it can be so upsetting and you can feel so alone, but with 7.5 million people living with this disease, you are not, said Lowes. This site is a wonderful tool that people struggling with psoriasis can use to their benefit because I want people to feel, you know, that we are a large community that we support each other. I want to encourage people to find a doctor they can trust, to find a treatment that works for them and I just want people to know that it is possible to get to a place where youre not limiting fashion and style and being with our family and things like that.

Lowes appears on the final season of Scandal which airs Thursdays on WATE 6 On Your Side. When asked if she knows how the show will end, Lowes said she is under lock-and-key.

We are not allowed to say anything, but I can assure you that this will be the final season of Scandal and the writers are leaving it all on the dance floor and it is going to be a wild and crazy ride for sure.

Read more from the original source:
‘Scandal’ actress Katie Lowes opens up about psoriasis – WATE 6 On Your Side

Posted in Psoriasis | Comments Off on ‘Scandal’ actress Katie Lowes opens up about psoriasis – WATE 6 On Your Side

Oasis fan mistook Liam Gallagher’s psoriasis for cocaine at … – Metro – Metro

Posted: June 23, 2017 at 5:48 am

Liam Gallagher (Picture: Rex)

Bad boy rocker Liam Gallagher has many a vivid tale of debauchery to proudly share with the world but this particular story makes even him scratch his head in disbelief.

The former Oasis frontman recalled upon his first experiences of Glastonbury, when the band first played the festival in 1994 and told a backstage story in which a fan mistook hispsoriasis a flaky and itchy skin condition for cocaine.

I remember coming off stage and I got my clothes robbed, told Liam in a recent interview with Noisey.

I remember meeting someone, some very strange kid, who come up to me and thought I had cocaine in my hair, he said.

I got psoriasis so I had obviously been scratching it during the day and that, and there were little white bits and shit, the singer eloquently put.

They were takingit out of my hair and putting it on their gums and putting it up their fucking nose. I went like, Okay

I think we were a bit too laddy or English for them the Morning Glory singer added.

Miley Cyrus praises role model Dolly Parton as she reveals why she feels ‘genderless’

10 pictures of Glastonbury day 2 looking amazing

Glastonbury to hold minute’s silence to honour victims of London and Manchester attacks

Meanwhile, Liam was also confirmed to appear at Worthy Farm on the Pyramid Stage this year, as well as showing that he also has the chops for spitting grime bars.

Speaking to Christian OConnell on Absolute Radio, he told how his second son Gene really likes the Skepta stuff prompting the host to encouraging the Wonderwall hitmaker to have a go at so-called Skepta stuff.

It was a little inaudible at first but on a second listen we could tell that he rapped: You aint road! The only road you sweep are paved with gold.

Liam has reportedly finished work on his solo album As You Were, and will release it in the autumn only a month before brother Noels new album.

We wonder how much of his sons grime influence will have on his new record.

MORE: Liam Gallaghers had a pop at Liam Payne, just for a change

MORE: Skepta ave it mate: You need watch Liam Gallagher spit some grime

See the original post:
Oasis fan mistook Liam Gallagher’s psoriasis for cocaine at … – Metro – Metro

Posted in Psoriasis | Comments Off on Oasis fan mistook Liam Gallagher’s psoriasis for cocaine at … – Metro – Metro

Dara Torres Is ‘Ready to Talk’ to Her Daughter About Body Confidence After Managing Psoriasis and an Eating Disorder – PEOPLE.com

Posted: at 5:48 am

Between overcoming an eating disorder in college and managing her psoriasis for the last 25 years, swimmer Dara Torres is fully prepared for any body image conversations her 11-year-old daughter Tessathrows her way.

The 12-time Olympic medalist says the questionshave already started.

She has talked to me actually a few weeks ago about body confidence, because she had to go to an end of the year school party and it was a pool party, and she wanted to talk to me about her body and what swimsuits to wear and having confidence, Torres, 50, tells PEOPLE. And it was the first time she ever really approached me about that on her own. So I was proud of her for being open about that.

Torres says her own background made it easier to relate.

I think the fact that I had an eating disorder in college, and then developing plaque psoriasis, I definitely had some confidence issues and self-esteem issues, she says. So I definitely am completely educated and ready to talk to her about any body image questions she has.

RELATED VIDEO:9 Celebrities Who Struggle with Psoriasis

Dealing with her plaque psoriasis as a young swimmer Torres first noticed the itchy, red rashes as a 25-year-old during the run up to the 1992 Barcelona Games was tough at first.

I was really embarrassed by it, because my business suit is a swimsuit. I needed to be on the pool deck in a little Speedo with these red patches all over me, Torres says.

But gaining the confidence to ignore her psoriasis was key to managing it, particularly because Torres is triggered by stress. Now she works to share that strength with other psoriasis sufferers by working withOtezla and Celgene on their Show More of You campaign.

I want to get the word out that you can have confidence and you can follow your dreams, Torres says. You can be yourself and not worry about what other people think.

See original here:
Dara Torres Is ‘Ready to Talk’ to Her Daughter About Body Confidence After Managing Psoriasis and an Eating Disorder – PEOPLE.com

Posted in Psoriasis | Comments Off on Dara Torres Is ‘Ready to Talk’ to Her Daughter About Body Confidence After Managing Psoriasis and an Eating Disorder – PEOPLE.com

Liam Gallagher says that Oasis fans tried to snort his psoriasis at … – NME.com

Posted: June 22, 2017 at 4:45 am

Liam Gallagher has recalled Oasis first Glastonbury appearance, revealing how fans of the band tried to snort hispsoriasis backstage.

The Britpop groupfirst played Glasto in 1994 and Gallagher remembered a story from that years festival in a recent interview with Noisey.

I remember coming off stage and I got my clothes robbed, Gallagher said. I [also] remember meeting someone, some very strange kid, who come up to me and thought I had cocaine in my hair.

Liam explained: I got psoriasis [skin condition that causes itchy, scaly rashes] so I had obviously been scratching it during the day and that, and there were little white bits and shit. They were takingit out of my hair and putting it on their gums and putting it up their fucking nose. I went like, Okay’.

Watch in the video below at the 2.04 mark.

Earlier today, bookies announced 12/1 odds that Liam and Noel would reunite at Glastonbury 2017.Liamis set to play The Other Stage on Saturday afternoonwhereas his brother is also due to appeartointroduce a special screening of Oasis movie Supersonic.

Elsewhere in the interview, Gallaghershared an anecdote about hanging out with Steve Cooganand gavehis take on why Oasis never fully broke America.

Liam said: I think we were a bit too laddy or English for themIm quite happy with the way it went down in America to be honest. I think if we got big in America id be a proper c*nt.

Originally posted here:
Liam Gallagher says that Oasis fans tried to snort his psoriasis at … – NME.com

Posted in Psoriasis | Comments Off on Liam Gallagher says that Oasis fans tried to snort his psoriasis at … – NME.com

Novartis’ Cosentyx and Eli Lilly’s Taltz Bring Disruption to the Psoriasis Market as IL-17 Share Increases Dramatically – PR Newswire (press release)

Posted: at 4:45 am

So, what does this mean for other biologics in PsO? According to the report, Humira has seen a 16% offset to share over the past year and Enbrel has given up more than 20%. Although future projections show this erosion curve to continue, actual offsets may come at a slower pace, particularly for Humira, which is extremely well-entrenched as a first line biologic, as well as the preferred biologic for certain PsO patient types. Furthermore, AbbVie dominates when it comes to perceptions about manufacturer support for patients, providers, and the dermatology community.

Janssen’s Stelara has carved out a solid position as the leading alternative mechanism biologic; however, the IL-17s are expected to catch up in the next six months, essentially flattening Stelara’s growth. Indeed, among those expecting to increase their use of IL-17s, close to a third expect a corresponding decrease in the use of Stelara.

Lastly, Celgene’s Otezla has maintained a solid position as a psoriasis treatment and dermatologists do project gains in patients with mild and moderate disease. However, only half of the current Otezla patients are classified as “well-managed” compared to 71% of biologic-treated patients. Furthermore, dermatologists identified multiple barriers to increased use of Otezla, including market access challenges, issues with GI tolerability, and sustained efficacy. Until additional oral small molecule products enter the psoriasis market, Otezla has the corner on a market very much in demand by patients.

The next wave of this study, RealTime Dynamix, will field in August and further drivers behind the evolution of this market will be explored next month in RealWorld Dynamix: Psoriasis, a large scale syndicated chart analysis of over 1,000 biologic/apremilast treated patients that have recently switched brands.

All company, brand or product names in this document are trademarks of their respective holders

About Spherix Global Insights Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact: Lynn Price, Immunology Franchise Head Email: info@spherixglobalinsights.com http://www.spherixglobalinsights.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novartis-cosentyx-and-eli-lillys-taltz-bring-disruption-to-the-psoriasis-market-as-il-17-share-increases-dramatically-300477250.html

SOURCE Spherix Global Insights

Home

Read the original post:
Novartis’ Cosentyx and Eli Lilly’s Taltz Bring Disruption to the Psoriasis Market as IL-17 Share Increases Dramatically – PR Newswire (press release)

Posted in Psoriasis | Comments Off on Novartis’ Cosentyx and Eli Lilly’s Taltz Bring Disruption to the Psoriasis Market as IL-17 Share Increases Dramatically – PR Newswire (press release)

Tofacitinib Assessed for Efficacy in Nail Psoriasis – Monthly Prescribing Reference (registration)

Posted: at 4:45 am

June 20, 2017

Improvement in nail psoriasis severity at 16 weeks vs placebo; maintained through 52 weeks

HealthDay News Tofacitinib is associated with improvements in nail psoriasis, according to a study published in the July issue of the Journal of the American Academy of Dermatology.

Joseph F. Merola, MD, from Brigham and Women’s Hospital in Boston, and colleagues examined the efficacy of tofacitinib for nail psoriasis treatment over 52 weeks in two identical phase 3 studies. Patients were randomized to receive tofacitinib 5 mg (487 patients), tofacitinib 10 mg (476 patients), or placebo (233 patients) twice daily. Placebo-treated patients were re-randomized at week 16.

The researchers found that significantly more patients receiving tofacitinib 5mg and tofacitinib 10mg versus placebo achieved a 50% reduction in the Nail Psoriasis Severity Index (NAPSI) score from baseline (NAPSI50) (32.8 and 44.2, respectively, versus 12.0 percent), NAPSI75 (16.9 and 28.1, respectively, versus 6.8 percent), and NAPSI100 (10.3 and 18.2, respectively, versus 5.1 percent) at week 16. The improvements were maintained to week 52.

“Tofacitinib treatment resulted in improvements in nail psoriasis versus placebo at week 16; improvements were maintained over 52 weeks,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which manufactures tofacitinib and funded the study.

Abstract Full Text

See the original post here:
Tofacitinib Assessed for Efficacy in Nail Psoriasis – Monthly Prescribing Reference (registration)

Posted in Psoriasis | Comments Off on Tofacitinib Assessed for Efficacy in Nail Psoriasis – Monthly Prescribing Reference (registration)

Marijuana May Be The Hero Psoriasis Patients Need – The Fresh Toast

Posted: June 21, 2017 at 3:46 am

Psoriasis, an autoimmune disease that causes itchy, red scale to appear on the skin, is no stranger to the three million people who suffer from it. While itchiness is the most common symptom, in many cases patients also experience painfully inflamed tendons as well joint stiffness.

Unfortunately, the condition remains incurable, but scientists are pointing to a likely remedy to make the disease less insufferable. Thats right, cannabis has some pretty awesome effects on psoriasis.

In a 2007 study researchers concluded that cannabinoids can inhibit the buildup of dead skin cells and other symptoms of psoriasis. The study, which was published in the Journal of Dermatological Science, used different types of cannabinoids including, THC (cannabis most psychoactive component), CBD (one of cannabis least active ingredients) and cannabinol and cannabigerol (other cannabis compounds) all of which were used to examine cannabis anti-inflammatory effects.

Researchers concluded, The cannabinoids tested all inhibited keratinocyte proliferation in a concentration-dependent manner. In other words, the four different cannabinoids they tested were all able to block the buildup of dead skin.

Why does this matter? Well, psoriasis is, essentially, the rapid accumulation of dead skin cells on the surface of the epidermis. So cannabis ability to stop that accumulation is a win, for people battling the inherited disease.

In a not so formal study, researchers at Gwynedd Cannabis Club in Wales, conducted a 9 day experiment in which they treated one subject with acute psoriasis, using cannabis oil. Prior to the experiment, the subject had been using a chemotherapy drug called Methotrexate, known to treat rheumatoid arthritis and psoriasis.

However, the side effects of the drug included fever, diarrhea and increased the chance of infection.

During the 9 day study, the subject was given three doses of topical daily, for nine. Following the treatment, the subject reported no adverse side effects and even noted how she was able to go swimming with her family, which is something she had been limited in doing, due to her psoriasis.

Now, while this study is majority anecdotal, it still serves as another example of cannabis healing powers for people with psoriasis especially in cases where conventional pharmaceuticals cant seem to get it right.

Read the original post:
Marijuana May Be The Hero Psoriasis Patients Need – The Fresh Toast

Posted in Psoriasis | Comments Off on Marijuana May Be The Hero Psoriasis Patients Need – The Fresh Toast

La La Anthony’s Secret to Fighting Psoriasis Is Probably in Your Kitchen – PEOPLE.com

Posted: June 19, 2017 at 6:45 pm


PEOPLE.com
La La Anthony's Secret to Fighting Psoriasis Is Probably in Your Kitchen
PEOPLE.com
It is just gentle enough on my sensitive skin, which is really hard to find when you do have psoriasis, the star, who says she confides in close friend and fellow psoriasis-sufferer Kim Kardashian West about which medications work and which don't

Continued here:
La La Anthony’s Secret to Fighting Psoriasis Is Probably in Your Kitchen – PEOPLE.com

Posted in Psoriasis | Comments Off on La La Anthony’s Secret to Fighting Psoriasis Is Probably in Your Kitchen – PEOPLE.com

Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx – Zacks.com

Posted: June 15, 2017 at 8:48 pm

Novartis AG (NVS – Free Report) announced positive data on arthritis drug Cosentyx from two phase III studies at the Annual European Congress of Rheumatology (EULAR 2017), in Madrid.

Cosentyx, fully human monoclonal antibody, is already approved in the U.S. and EU for the treatment of moderate-to-severe plaque psoriasis. The drug is also approved in the EU for the treatment of adults with ankylosing spondylitis (AS) who have responded inadequately to conventional therapy, such as non-steroidal anti-inflammatory drugs. The drug is also instrumental for the treatment of active psoriatic arthritis (PsA) in adults when the response to disease modifying anti-rheumatic drug therapy is unsatisfactory.

In Jan 2016, Cosentyx obtained the FDA approval for the treatment of adults with active ankylosing spondylitis and for the treatment of adults with active psoriatic arthritis.

The data shows sustained improvement in the signs and symptoms for active AS at three years. The new data also revealed that Cosentyx provides rapid and sustained pain relief in patients with PsA out to 2 years.

Data from the phase III study, MEASURE 1 extension study, showed 80% of AS patients consistently achieved an ASAS 20 response at 3 years, in tandem with previous findings from the FUTURE 1 study on Cosentyx for active PsA. Additionally, a 2-year post-hoc analysis of the FUTURE 2 study evaluated Cosentyx in PsA, where 99% patients reported moderate-to-extreme pain or discomfort before initiating treatment. At week 3, half of the treated with Cosentyx reported clinically meaningful improvements in pain of over 20%, as measured by Visual Analogue Scale.

Meanwhile, patient recruitment is underway for the new head-to-head clinical trial, EXCEED, to evaluate the superiority of Cosentyx versus AbbVies (ABBV – Free Report) Humira in PsA.

Novartis has outperformed the Zacks classified industry over the last six months. The stock has rallied 12.2% compared with the Large Cap Pharmaceuticals industrys gain of 4.5%.

The uptake of Cosentyx has been strong and the company has grabbed market shares from rivals, Humira and Amgens (AMGN – Free Report) Enbrel. Cosentyx achieved blockbuster status in 2016 recording over $1 billion of sales.

Novartis expects the next growth phase to begin in 2018 driven by Cosentyx (in all three indications psoriasis, psoriatic arthritis and ankylosing spondylitis) Entresto, and Kisqali and a deep pipeline with candidates like CTL019, BAF312, AMG 334, RTH258. Going forward, we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis.

Zacks Rank & Key Pick

Novartis currently carries a Zacks Rank #3 (Hold).

A better-ranked stock in healthcare sector include VIVUS, Inc. (VVUS – Free Report) which sports a Zacks Rank #1 (Strong Buy). You can seethe complete list of todays Zacks #1 Rank stocks here.

VIVUSs loss per share estimates lessened from 50 cents to 39 cents for 2017 in the last 30 days. The company posted positive earnings surprises in all four trailing quarters with average beat of 233.69%.

3 Stocks to Ride a 588% Revenue Explosion

At Zacks, we’re mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold.

By last year, it was already generating $8 billion in global revenues. By 2020, it’s predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce “the world’s first trillionaires,” but that should still leave plenty of money for those who make the right trades early. See Zacks’ Top 3 Stocks to Ride This Space >>

Read more from the original source:
Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx – Zacks.com

Posted in Psoriasis | Comments Off on Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx – Zacks.com

Tofacitinib may be an effective treatment for nail psoriasis – 2 Minute Medicine

Posted: June 14, 2017 at 3:47 am

1. In a posthoc analysis of 2, phase 3 randomized controlled trials of over 1000 patients with moderate-to-severe plaque psoriasis, tofacitinib (an oral Janus kinase inhibitor) treatment demonstrated significantly improved clinical nail psoriasis severity scores at 16 weeks compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Psoriasis is a chronic, inflammatory skin disease associated with clinical manifestations of the nail that include pitting, onycholysis, subungual hyperkeratosis, and discoloration. Nail psoriasis may severely impair function and is associated with significantly greater disease severity and impact on patient quality of life than psoriasis without nail involvement. Tofacitinib is an oral Janus kinase inhibitor that has previously demonstrated efficacy and tolerability in phase 3 clinical trials of moderate-to-severe chronic plaque psoriasis. The purpose of this study was to assess the effect of tofacitinib on nail psoriasis.

This study is a post-hoc pooled analysis of two phase 3 clinical trials evaluating the efficacy of tofacitinib in 1196 patients with nail psoriasis. At the conclusion of the study, both the 5mg and 10mg twice-daily administrations of tofacitinb demonstrated clinically significant improvement in nail psoriasis compared to placebo at 16 weeks with effects maintained at 52 weeks. The results of this study support the use of tofacitinib as a potential treatment modality for nail psoriasis. This study is strengthened by its large sample size, multiple trial sites, randomization, double blinding, and comparison to placebo. The interpretation of study results is limited by the use of only objective measures to assess severity without incorporating subjective patient-reported outcomes. Moreover, non-responders were discontinued from the study at 28 weeks and not included in analysis. Multi-center prospective trials that include patient-reported outcome measures to assess improvements in severity may help improve the validity and of the study.

Click to read the study in JAAD

Relevant Reading: Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

In-Depth [randomized controlled trial]: This study conducted a pooled posthoc analysis of two identical 52-week multi-site phase 3 randomized controlled trials evaluating the efficacy of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis with nail involvement. Patients in both trials were randomized 2:2:1 to receive tofacitinib 5mg or 10mg, or placebo twice daily. Overall, this study identified 1196 patients with nail involvement of the original 1859 patients with psoriasis recruited in the initial studies. Patients were determined to be moderate-to-severe via a Psoriasis Area and Severity Index score 12, Physicians Global Assessment of moderate or severe, and affected body surface area 10%. Improvements in severity were assessed using the Nail Psoriasis Severity Index (NAPSI). The proportion of patients that demonstrated a 50%, 75% or 100% reduction from baseline in NAPSI score (NAPSI50, NAPSI75 and NAPSI100) were calculated and compared between treatment arms. Patients treated with tofacitinib demonstrated improvement in pitting, onycholysis, subungual hyperkeratosis, and discoloration. Moreover, treatment with tofacitinib demonstrated significantly greater proportions of patients that achieved NAPSI50, NAPSI75 and NAPSI100 compared to placebo at 16 weeks (p

Image: PD

20172 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

2 Minute Medicines The Classics in Medicine: Summaries of the Landmark Trials is available now in paperback and e-book editions.

This text summarizes the key trials in:General Medicine and Chronic Disease, Cardiology, Critical and Emergent Care, Endocrinology, Gastroenterology, Hematology and Oncology, Imaging, Infectious Disease, Nephrology, Neurology, Pediatrics, Psychiatry, Pulmonology, and Surgery.

Continue reading here:
Tofacitinib may be an effective treatment for nail psoriasis – 2 Minute Medicine

Posted in Psoriasis | Comments Off on Tofacitinib may be an effective treatment for nail psoriasis – 2 Minute Medicine

Page 11234..1020..»